Using Chinese herbal medicine for recovery after heart surgery
Prospective Cohort Study on Fuzheng Yangxin Prescription For Rapid Rehabilitation of Patients With Qi-Yin Deficiency Syndrome After Coronary Artery Bypass Grafting
This study is testing whether a traditional Chinese herbal medicine can help people recover faster after heart surgery compared to a placebo.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 25 Years to 85 Years |
| Sex | All |
| Sponsor | Peking University Third Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06961136 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the effects of the Fuzheng Yangxin prescription on the rapid rehabilitation of patients who have undergone coronary artery bypass grafting (CABG) and are diagnosed with Qi-Yin deficiency syndrome. The study aims to assess the efficacy of this traditional Chinese herbal treatment compared to a placebo in improving recovery outcomes post-surgery. Participants will be monitored for their recovery progress and overall health status following the intervention. The study is particularly relevant given the rising prevalence of coronary heart disease and the increasing number of CABG procedures performed annually.
Who should consider this trial
Good fit: Ideal candidates for this study are patients who have undergone CABG and exhibit symptoms of Qi-Yin deficiency.
Not a fit: Patients with severe postoperative complications or those allergic to the herbal treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a novel herbal treatment option to enhance recovery for patients after heart surgery.
How similar studies have performed: While the use of traditional Chinese medicine in post-operative care is gaining interest, this specific approach has not been widely tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who received coronary artery bypass surgery with syndrome differentiation of Qi-Yin deficiency after operation Exclusion Criteria: * ① Patients allergic to Fuzheng Yangxin Fang granules * Patients with postoperative cold and fever ③ Patients with severe postoperative hepatic and renal insufficiency ④ Other circumstances: Concurrent valvular surgery or other cardiac surgery, end-stage malignant tumor, uncontrolled infection, bleeding, progressive degenerative systemic disease, severe brain injury, multiple organ failure, other vital organ dysfunction such as severe liver impairment, severe heart failure or cardiogenic shock, inability to tolerate surgery, etc.
Where this trial is running
Beijing, Beijing Municipality
- Peking university third hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Yichen Gong Doctor
- Email: 18611693463@126.com
- Phone: 8618611693463
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.